DEA Action Supports NP, PA Prescribing Authority for Opioid Addiction Treatment
January 23rd 2018A new measure announced by the Drug Enforcement Administration (DEA) will expand access to opioid addiction treatment by allowing nurse practitioners (NPs) and physician assistants (PAs) in underserved areas to prescribe and dispense buprenorphine.
FDA Announces Efforts to Ease Provider Access to Clinical Trial Info
January 17th 2018The FDA has announced new efforts to enhance transparency around drug approval decisions by launching a pilot program aimed at improving health care providers' access to key information related to new drugs, according to a statement.
Out-of-Sequence Packaging Forces Manufacturer to Recall Oral Contraceptives
May 30th 2017Lupin Pharmaceuticals Inc. has issued a nationwide recall of 1 lot of its oral contraceptive tablets Mibelas 24 Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate) because of out-of-sequence tablet packaging and missing expiration and lot information.